2008
Advances in the Treatment of Metastatic Non–Small-Cell Lung Cancer With Chemotherapy and Targeted Agents
Lilenbaum R, Herbst R. Advances in the Treatment of Metastatic Non–Small-Cell Lung Cancer With Chemotherapy and Targeted Agents. Clinical Pulmonary Medicine 2008, 15: 352-358. DOI: 10.1097/cpm.0b013e31818cd61f.Peer-Reviewed Original ResearchCell lung cancerMetastatic NSCLCOverall survivalLung cancerPatient outcomesAdvanced metastatic NSCLCThird-line settingBest supportive careProgression-free survivalAntiangiogenic agent bevacizumabOverall patient survivalPatient selection criteriaOngoing clinical trialsEpidermal growth factor receptorGrowth factor receptorRefractory settingAgent bevacizumabSupportive careTargeted agentsOptimal therapyChemotherapeutic regimensPatient survivalClinical trialsResponse rateMaximal benefit
2006
Use of Novel Second-Line Targeted Therapies in Non–Small Cell Lung Cancer
Massarelli E, Herbst RS. Use of Novel Second-Line Targeted Therapies in Non–Small Cell Lung Cancer. Seminars In Oncology 2006, 33: 9-16. PMID: 16472704, DOI: 10.1053/j.seminoncol.2005.12.007.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerOverall response rateEpidermal growth factor receptorCell lung cancerLung cancerResponse rateSecond-line therapeutic approachStandard cytotoxic regimensFirst-line treatmentNew treatment optionsLung cancer casesQuality of lifeNew chemotherapeutic agentsCytotoxic regimensGrowth factor receptorRefractory settingMetastatic diseaseRefractory diseaseLocal therapyNSCLC treatmentTreatment optionsCancer deathTargeted therapyTreatment outcomesCancer cases